Home News Potential New Standard for High-Risk, Pediatric B-Cell Lymphoma back to News
minute read
Adding rituximab (Rituxan) to standard lymphomes malins B (LMB) chemotherapy in children and adolescents with high-risk, mature B-cell lymphoma significantly improved event-free and overall survival, an international phase III trial showed.
Topics: Press Coverage
13001 East 17th Place
Aurora, CO 80045
303.724.5375
© 2024 The Regents of the University of Colorado, a body corporate. All rights reserved.
Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.
